These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 37218325)

  • 1. [Educational Project of Self-Removal of the Intravenous Central Venous Access Port Guided by Patients with Advanced Colorectal Cancer Instructed by a Nurse in the University Hospital].
    Kuribayashi M; Nomura K; Yarimizu A; Hirata M; Ohashi E; Kimura K; Takenaka Y; Song J; Yanagawa T; Nishimura Y; Beppu N; Uchino M; Ikeuchi H; Ikeda M; Kataoka K
    Gan To Kagaku Ryoho; 2023 May; 50(5):623-626. PubMed ID: 37218325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Central venous access port-related complications in outpatient chemotherapy for colorectal cancer.
    Inaba Y; Yamaura H; Sato Y; Najima M; Shimamoto H; Nishiofuku H; Ura T; Muro K
    Jpn J Clin Oncol; 2007 Dec; 37(12):951-4. PubMed ID: 18057011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
    Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A;
    Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central venous port system-related complications in outpatient chemotherapy for colorectal cancer.
    Tsutsumi S; Fukasawa T; Fujii T; Tabe Y; Kigure W; Asao T; Kuwano H
    Hepatogastroenterology; 2012 Jun; 59(116):1079-80. PubMed ID: 22580658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The central vein access port and catheter in outpatient chemotherapy for colorectal cancer: a retrospective study of 101 patients.
    Sawayama H; Hayashi N; Watanabe M; Takamori H; Beppu T; Baba H
    Surg Today; 2012 Jan; 42(1):29-34. PubMed ID: 22105529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and toxicity of fluorouracil, leucovorin plus oxaliplatin (FOLFOX4 and modified FOLFOX6) followed by fluorouracil, leucovorin plus irinotecan(FOLFIRI)for advanced or metastatic colorectal cancer--case studies.
    Ohtani H; Arimoto Y; Nishio K; Kanamiya Y; Oba H; Adachi K; Shintani M; Nakamura R; Yui S
    Gan To Kagaku Ryoho; 2008 Oct; 35(10):1769-74. PubMed ID: 18931586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOLFIRI as second-line chemotherapy after failure of FOLFOX4 in advanced colorectal cancer: a Korean single-center experience.
    Kim JH; Park SJ; Park MI; Moon W; Kim SE; Ku KH; Song SE; Kim JH
    Korean J Gastroenterol; 2014 Jan; 63(1):18-24. PubMed ID: 24463284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Assessment of quality of life by questionnaires between S-1/CPT-11 and mFOLFOX6 in patients with advanced colorectal cancer].
    Tokunaga Y; Sasaki H; Matsueda S
    Gan To Kagaku Ryoho; 2011 Jul; 38(7):1127-31. PubMed ID: 21772096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Modified FOLFOXIRI+α in the Treatment of Advanced and Recurrent Colorectal Cancer: A Single-center Experience.
    Kobayashi K; Yamaguchi S; Ito S; Torashima Y; Inoue Y; Okada S; Enjoji T; Tetsuo H; Kuba S; Kosaka T; Adachi T; Hidaka M; Yamanouchi K; Kanetaka K; Takatsuki M; Eguchi S
    Intern Med; 2020 May; 59(10):1239-1245. PubMed ID: 32074573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: A retrospective observational study using an administrative database.
    Shinozaki E; Makiyama A; Kagawa Y; Satake H; Tanizawa Y; Cai Z; Piao Y
    PLoS One; 2021; 16(2):e0246160. PubMed ID: 33556095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Establishment of a Needle-Removal Method Considering Anticancer Drug Exposure after Continuous Administration of Fluorouracil Using an Infusion Pump].
    Furihata S; Yatsu N; Ohno R; Takamatsu N; Anami S
    Gan To Kagaku Ryoho; 2021 Jul; 48(7):939-943. PubMed ID: 34267032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis on safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (FOLFOXIRI) in advanced colorectal cancer].
    Cai Y; Deng R; Hu H; Zhang J; Ling J; Wu Z; Yang L; Li J; Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1045-1050. PubMed ID: 30269326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    Loupakis F; Cremolini C; Masi G; Lonardi S; Zagonel V; Salvatore L; Cortesi E; Tomasello G; Ronzoni M; Spadi R; Zaniboni A; Tonini G; Buonadonna A; Amoroso D; Chiara S; Carlomagno C; Boni C; Allegrini G; Boni L; Falcone A
    N Engl J Med; 2014 Oct; 371(17):1609-18. PubMed ID: 25337750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
    Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
    Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials.
    Petrelli F; Borgonovo K; Cabiddu M; Ghilardi M; Lonati V; Maspero F; Sauta MG; Beretta GD; Barni S
    Clin Colorectal Cancer; 2013 Sep; 12(3):145-51. PubMed ID: 23763824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.
    Falcone A; Ricci S; Brunetti I; Pfanner E; Allegrini G; Barbara C; Crinò L; Benedetti G; Evangelista W; Fanchini L; Cortesi E; Picone V; Vitello S; Chiara S; Granetto C; Porcile G; Fioretto L; Orlandini C; Andreuccetti M; Masi G;
    J Clin Oncol; 2007 May; 25(13):1670-6. PubMed ID: 17470860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognostic factors affecting the success of conversion chemotherapy in patients with unresectable liver metastases from initially colorectal cancer].
    Zhang WL; Zhou C; Deng YX; Hou ZL; Zhang LJ; Lin JZ; Pan ZZ; Lu ZH; Peng JH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Jan; 25(1):56-62. PubMed ID: 35067035
    [No Abstract]   [Full Text] [Related]  

  • 18. Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis.
    Liang XB; Hou SH; Li YP; Wang LC; Zhang X; Yang J
    Chin Med J (Engl); 2010 Nov; 123(22):3314-8. PubMed ID: 21163137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Administration of chemotherapy via the median cubital vein without implantable central venous access ports: port-free chemotherapy for metastatic colorectal cancer patients.
    Yoshida Y; Hoshino S; Aisu N; Naito M; Tanimura S; Mogi A; Tanaka T; Hirata K; Tamura K; Yamashita Y
    Int J Clin Oncol; 2015 Apr; 20(2):332-7. PubMed ID: 24811333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
    Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
    J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.